Trial · NCT00410761
Adverse events1,188
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,188
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Randomized Treatment Period: Vandetanib 300 mg | 10 | 231 | 12 |
| other | Vertigo | Ear and labyrinth disorders | Randomized Treatment Period: Placebo | 2 | 99 | 2 |
| other | Vertigo | Ear and labyrinth disorders | Open-Label Treatment Period: Vandetanib 300 mg/Vandetanib 300 mg | 1 | 109 | 1 |
| other | Vertigo | Ear and labyrinth disorders | Open-Label Treatment Period: Placebo/Vandetanib 300 mg | 5 | 79 | 5 |
| other | Hypothyroidism | Endocrine disorders | Randomized Treatment Period: Vandetanib 300 mg | 16 | 231 | 19 |
| other | Hypothyroidism | Endocrine disorders | Randomized Treatment Period: Placebo | 0 | 99 | 0 |
| other | Hypothyroidism | Endocrine disorders | Open-Label Treatment Period: Vandetanib 300 mg/Vandetanib 300 mg | 1 | 109 | 1 |
| other | Hypothyroidism | Endocrine disorders | Open-Label Treatment Period: Placebo/Vandetanib 300 mg | 1 | 79 | 1 |
| other | Corneal Opacity | Eye disorders | Randomized Treatment Period: Vandetanib 300 mg | 11 | 231 | 11 |
| other | Corneal Opacity | Eye disorders | Randomized Treatment Period: Placebo | 0 | 99 | 0 |
| other | Corneal Opacity | Eye disorders | Open-Label Treatment Period: Vandetanib 300 mg/Vandetanib 300 mg | 0 | 109 | 0 |
| other | Corneal Opacity | Eye disorders | Open-Label Treatment Period: Placebo/Vandetanib 300 mg | 4 | 79 | 4 |
| other | Vision Blurred | Eye disorders | Randomized Treatment Period: Vandetanib 300 mg | 19 | 231 | 23 |
| other | Vision Blurred | Eye disorders | Randomized Treatment Period: Placebo | 1 | 99 | 1 |
| other | Vision Blurred | Eye disorders | Open-Label Treatment Period: Vandetanib 300 mg/Vandetanib 300 mg | 1 | 109 | 1 |
| other | Vision Blurred | Eye disorders | Open-Label Treatment Period: Placebo/Vandetanib 300 mg | 5 | 79 | 5 |
| other | Abdominal Pain | Gastrointestinal disorders | Randomized Treatment Period: Vandetanib 300 mg | 33 | 231 | 50 |
| other | Abdominal Pain | Gastrointestinal disorders | Randomized Treatment Period: Placebo | 5 | 99 | 6 |
| other | Abdominal Pain | Gastrointestinal disorders | Open-Label Treatment Period: Vandetanib 300 mg/Vandetanib 300 mg | 2 | 109 | 2 |
| other | Abdominal Pain | Gastrointestinal disorders | Open-Label Treatment Period: Placebo/Vandetanib 300 mg | 5 | 79 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00410761/events